This quarter of 2024 were 3.8 billion, an increase of 4% in U.S. dollars and 5% in local currency terms compared to the first quarter of 2023, the increase was mainly driven by broad-based growth from generics products across all our segments globally, including strong contribution from generics travel made in the U.S., continued strong growth in Ocedo as well as the Jovi in our Europe and international market segments.

May 8, 2024 / CFO / receipt, needs a key / Eli Khalif, CFO | earnings call 2024-05-08 | transcript a650ec48-33e0-4175-a167-672c368e12e0 | chars 17746-18169 | segment 18